RxDoctor Payments Data

Katherine Hill

Family · Annapolis, MDNPI 1598204372

Payments from drug & device makers

$1,944in general payments, 2019–2025

Across 50 payments — averaging $38.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$925
  • Sumitomo Pharma America, Inc.$386
  • AbbVie$177
  • Astellas Pharma US Inc$146
  • Boston Scientific$131
  • Baxter Healthcare$119
  • plus $59 from 3 others

What the payments were for

  • Speaking & faculty fees$1005%
  • Travel & lodging$27314%
  • Food & beverage$1,47176%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,944 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$87,346
Medicare patients
579
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron253$164,936
GemtesaVibegron194$148,192
EstringEstradiol57$30,001
Estradiol224$16,108
PremarinEstrogens, Conjugated37$15,672
Methenamine Hippurate115$5,753
Trospium Chloride ErTrospium Chloride22$5,640
Mirabegron ErMirabegron12$4,875
Tolterodine Tartrate ErTolterodine Tartrate19$2,527
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst112$1,787
Fosfomycin Tromethamine13$1,704
Solifenacin Succinate27$1,439
Trospium Chloride38$1,350
Clobetasol Propionate29$755
Oxybutynin Chloride ErOxybutynin Chloride22$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$146$164,936253 claims
Sumitomo Pharma America, Inc.Gemtesa$386$148,192194 claims
PfizerEstring, Premarin$24$45,67394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →